Significance Statement
======================

The development of new antidepressants effective in the treatment of resistant depression is urgently required. Rapid and sustained antidepressant actions of the N-methyl-D-aspartate receptor antagonist ketamine are the most important discovery in half a century of depression research. Similar to ketamine, the metabotropic glutamate 2/3 receptor antagonist MGS0039 shows rapid and sustained antidepressant effects in the social defeat stress model. Long-lasting synaptogenesis in the medial prefrontal cortex and hippocampus might be implicated in the sustained antidepressant effect of MGS0039. This study suggests that metabotropic glutamate 2/3 receptor antagonists would be potential therapeutic drugs for depression.

Introduction {#s1}
============

Depression is one of the most prevalent psychiatric disorders and the leading cause of disability worldwide. According to the World Health Organization, more than 350 million individuals of all ages suffer from depression ([@CIT0043]). Although current antidepressants are generally effective, the full therapeutic benefit of these therapies may require several weeks to bring about changes in mood and/or behavior. Additionally, approximately one-third of patients with depression fail to respond to current pharmacotherapy. Therefore, the development of new antidepressants effective in the treatment of resistant depression is urgently required ([@CIT0006]; [@CIT0019]; [@CIT0032]).

The *N*-methyl-D-aspartate (NMDA) receptor antagonist ketamine shows rapid and sustained antidepressant effects in depressed patients, including those with treatment-resistant disease ([@CIT0004]; [@CIT0050]; [@CIT0001]; [@CIT0040]). Recent meta-analyses indicated that ketamine exhibited a greater potency of antidepressant effects compared with other NMDA receptor antagonists ([@CIT0035]; [@CIT0021]). In addition, others have reported rapid and long-lasting antidepressant-like effects for ketamine in animal models of depression ([@CIT0048]; [@CIT0030]; [@CIT0027]; [@CIT0029]; [@CIT0051], [@CIT0045]; [@CIT0052]; [@CIT0041]). Accumulating evidence suggests that metabotropic glutamate 2/3 (mGlu2/3) receptor antagonists, such as MGS0039 and LY341495, evoke antidepressant-like activities in rodents ([@CIT0007]; [@CIT0020]; [@CIT0049]; [@CIT0037]; [@CIT0024]; [@CIT0013]; [@CIT0002]; [@CIT0022]; [@CIT0015]; [@CIT0042]). Furthermore, mGlu2/3 receptor antagonists have been reported to share similar efficacy in rodents and neural mechanisms with ketamine ([@CIT0023], [@CIT0025]), suggesting that mGlu2/3 receptor antagonists may have ketamine-like antidepressant actions. Although there is a report showing rapid and sustained antidepressant effects for LY341495 in a chronic unpredictable stress model ([@CIT0012]), these effects have not been fully addressed in the context of synaptic plasticity.

The purpose of this study was to compare the rapid and sustained antidepressant actions of MGS0039 and ketamine in the social defeat stress model. Additionally, we examined the effects of MGS0039 and ketamine on brain-derived neurotrophic factor (BDNF) -- TrkB signaling, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (GluA1), postsynaptic density protein 95 (PSD-95), and dendritic spine density in brain regions thought to be implicated in ketamine's antidepressant effects ([@CIT0003]; [@CIT0010]; [@CIT0012]; [@CIT0026]; [@CIT0054]; [@CIT0036]; [@CIT0051], [@CIT0045]; [@CIT0052]; [@CIT0042]; [@CIT0005]).

Materials and Methods {#s2}
=====================

Animals {#s3}
-------

Male adult C57BL/6 mice, aged 8 weeks (body weight 20--25 g, Japan SLC, Hamamatsu, Japan) and male adult CD1 (ICR) mice, aged 13 to 15 weeks (body weight \>40 g, Japan SLC) were used for the social defeat stress model. Animals were housed under controlled temperatures and 12-h-light/-dark cycles (lights on between 7:00 [am]{.smallcaps} and 7:00 [pm]{.smallcaps}) with ad libitum food (CE-2; CLEA Japan, Tokyo, Japan) and water. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Chiba University Institutional Animal Care and Use Committee.

Drugs {#s4}
-----

MGS0039, synthesized at Taisho Pharmaceutical Co. Ltd. (Saitama, Japan), was dissolved in 1/15 M phosphate buffer (pH 8.0). Ketamine hydrochloride, prepared from Ketalar (Daiichi Sankyo Pharmaceutical, Tokyo, Japan) was dissolved in 1/15 M phosphate buffer (pH 8.0). The doses of MGS0039 (1.0 mg/kg) and ketamine (10 mg/kg) were used as previously reported ([@CIT0007]; [@CIT0002]; [@CIT0039]; [@CIT0052]).

Social Defeat Stress Model {#s5}
--------------------------

The procedure of social defeat stress was performed as previously reported ([@CIT0016]; [@CIT0053]; [@CIT0051], [@CIT0045]; [@CIT0052]). Every day the C57BL/6 mice were exposed to a different CD1 aggressor mouse for 10 minutes total for 10 days. When the social defeat session ended, the resident CD1 mouse and the intruder mouse were housed in one-half of the cage separated by a perforated Plexiglas divider to allow visual, olfactory and auditory contact for the remainder of the 24-hour period. At 24 hours after the last session, all mice were housed individually. On day 11, a social avoidance test was performed to identify subgroups of mice that were susceptible and unsusceptible to social defeat stress. This was accomplished by placing mice in an interaction test box (42 × 42 cm) with an empty wire-mesh cage (10 × 4.5 cm) located at one end. The movement of the mice was tracked for 2.5 minutes, followed by 2.5 minutes in the presence of an unfamiliar aggressor confined in the wire-mesh cage. The duration of the subject's presence in the interaction zone (defined as the 8-cm-wide area surrounding the wire-mesh cage) was recorded by a stopwatch. The interaction ratio was calculated as the time spent in an interaction zone with an aggressor/time spent in an interaction zone without an aggressor. An interaction ratio of 1 was set as the cutoff: mice with scores \<1 were defined as susceptible to social defeat stress and those with scores ≥1 were defined as unsusceptible ([@CIT0053]). Only susceptible mice were used in the experiments.

Behavioral Tests {#s6}
----------------

On day 12, vehicle (10 mL/kg), MGS0039 (1.0 mg/kg), or ketamine (10 mg/kg) was injected i.p. ([Figure 1a](#F1){ref-type="fig"}). All behavioral tests were performed in the following order: locomotion (30 minutes after injection), tail suspension test (TST) (24 hours after injection), forced swimming test (FST) (48 hours after injection), and 1% sucrose preference test (SPT) (3 and 7 days after injection) ([Figure 1a](#F1){ref-type="fig"}). Mice were put into the test room 30 minutes before the behavioral tests. All tests were performed in a quiet room. After finishing all tests, mice were returned to the breeding room. The FST, TST, and SPT in mice are the most widely used behavioral assays for detecting potential antidepressant-like activity ([@CIT0008]; [@CIT0039]; [@CIT0051]; [@CIT0052]; [@CIT0009]; [@CIT0009]).

![Schedule of social defeat stress, treatment, and behavioral tests.\
a: The schedule of social defeat stress (10 days), drug treatment, and behavioral tests. Social defeat stress was performed from day 1 to day 10. Social interaction test was performed on day 11. Vehicle (10 mL/kg), MGS0039 (1 mg/kg), or ketamine (10 mg/kg) was administered i.p into susceptible mice on day 12. Locomotion test (LMT), tail suspension test (TST), and forced swim test (FST) were performed 0.5, 24, and 48 hours after a single injection, respectively. A 1% sucrose preference test (SPT) was performed 3 day (day 15) and 7 days (day 19) after a single injection. (b) The schedule of social defeat stress (10 days), drug treatment, and collection brain samples for western blot. Social interaction test was performed on day 11. Vehicle (10 mL/kg), MGS0039 (1 mg/kg), or ketamine (10 mg/kg) was administered i.p into susceptible mice on day 12. Brain samples were collected on day 20. (c) The schedule of social defeat stress (10 days), drug treatment, and collection brain samples for Golgi staining. Social interaction test was performed on day 11. Vehicle (10 mL/kg), MGS0039 (1 mg/kg), or ketamine (10 mg/kg) was administered i.p into susceptible mice on day 12. Brain samples were collected on day 20. Ket, ketamine; MGS, MGS0039; Veh, vehicle.](pyw08901){#F1}

### Locomotion {#s7}

Locomotion was measured using the SCANET MV-40 (MELQUEST Co., Ltd., Toyama, Japan). This system consists of a black square cage (565 × 565 mm) equipped with 2 crossing sensor frames of 72 (x axis) × 72 (y axis) pairs of near-infrared beam sensors, spaced 6 mm apart and at right angles to each other. The beam sensors thus form 2 parallel horizontal grids set at different heights. A transparent Plexiglas cage (560× 560 × 330 mm) for the mouse was centered inside the system. Each pair of sensors was scanned every 0.1 seconds to detect animal movement. Two different variables of horizontal movements could be monitored by the lower sensors: small horizontal movements of 12 mm or more (M1; 1 U=6 mm) and large horizontal movements of 60 mm or more (M2; 1 U = 6 mm). The locomotion was performed under house lighting, and the movement of the cumulative distance was recorded for 60 minutes. The cage was cleaned between testing session.

### TST {#s8}

The mice were taken from their home cage, and a small piece of adhesive tape was placed approximately 2 cm from the tip of the tail. A single hole was punched in the tape and the mice were hung individually on a hook. The immobility time of each mouse was recorded for 10 minutes. All mice were videoed, and then the immobility time of tail suspension was scored by a skilled observer who used stopwatch. Mice were considered immobile only when they hung passively and completely motionless.

### FST {#s9}

The mice were placed individually in a cylinder (diameter: 23 cm, height: 31 cm) containing 15 cm of water maintained at 23 ± 1°C. The animals were not able to touch the bottom of the cylinder. Animals were tested in an automated forced-swim apparatus by the SCANETMV-40 (MELQUEST Co., Ltd., Toyama, Japan). The cylinder was placed in a box with infrared cell sensors on the walls to detect swimming activity. The software set up a rectangle that circumscribed the body of an animal every 0.3 seconds. If the animals were out of the rectangle (i.e., a part of the animal body was detected outside the rectangle) 0.3 seconds after setting up the rectangle, the software counted as "movement (swimming)" in that period. Immobility was defined as such if the animal stayed within the same rectangle 0.3 seconds after setting up the rectangle. Immobility time was calculated from activity time as (total) − (active) time by using analysis software of the apparatus. Cumulative immobility time was scored for 6 minutes during the test.

### SPT {#s10}

Mice were exposed to water and 1% sucrose solution for 48 hours, followed by 4 hours of water and food deprivation and 1 hour exposure to 2 identical bottles: one was water and the other was 1% sucrose solution. The bottles containing water and sucrose were weighed before and at the end of this period and the sucrose preference was determined.

Western-Blot Analysis {#s11}
---------------------

Eight days after vehicle (10 mL/kg), MGS0039 (1.0 mg/kg), or ketamine (10 mg/kg) injection, the brain samples of prefrontal cortex (PFC), nucleus accumbens (NAc), dentate gyrus (DG), and CA1 and CA3 of the hippocampus were collected, since these brain regions are implicated in depression-like phenotype as described previously ([@CIT0051], [@CIT0045]; [@CIT0051]; [@CIT0009]) ([Figure 1b](#F1){ref-type="fig"}). Basically, tissue samples were homogenized in Laemmli lysis buffer. Aliquots (10 μg) of protein were measured using the DC protein assay kit (Bio-Rad, Hercules, CA) and incubated for 5 minutes at 95°C, with an equal volume of 125 mM Tris/HCl, pH 6.8, 20% glycerol, 0.1% bromophenol blue, 10% β-mercaptoethanol, and 4% sodium dodecyl sulfate and subjected to sodium dodecyl sulfate--polyacrylamide gel electrophoresis, using 10% mini-gels (Mini-PROTEAN TGX Precast Gel; Bio-Rad). Proteins were transferred onto polyvinylidene difluoride membranes using a Trans Blot Mini Cell (Bio-Rad). For immunodetection, the blots were blocked with 2% bovine serum albumin in Tris buffered saline + 0.1 % Tween 20 (TBST) for 1 hour at room temperature (RT) and kept with primary antibodies overnight at 4°C. The following primary antibodies were used: BDNF (1:1000, Santa Cruz Biotechnology, Inc.), phosphorylated-TrkB (Tyr 706) (1:200, Santa Cruz Biotechnology), and TrkB (80E3) (1:1000, Cell Signaling Technology), AMPA glutamate receptor 1 (GluA1) (1 μg/mL, Abcam, Cambridge, MA), and PSD-95 (1 μg/mL, Invitrogen, Carlsbad, CA). The next day, the blots were washed 3 times in TBST and incubated with horseradish peroxidase-conjugated anti-rabbit antibody (1:5000) for 1 hour at RT. After 3 final washes with TBST, the bands were detected using enhanced chemiluminescence plus the Western Blotting Detection system (GE Healthcare Bioscience). The blots then were washed 3 times in TBST and incubated with the primary antibody directed against β-actin. Images were captured with a Fuji LAS3000-mini imaging system (Fujifilm, Tokyo, Japan) and immunoreactive bands were quantified.

Golgi Staining {#s12}
--------------

Golgi staining was performed using the FD Rapid Golgi Stain TM Kit (FD Neuro Technologies, Inc., Columbia, MD) following the manufacturer's instructions. Eight days after a single administration of vehicle (10 mL/kg), MGS0039 (1.0 mg/kg), or ketamine (10 mg/kg), mice were deeply anesthetized with sodium pentobarbital, and brains were removed from the skull and rinsed in double distilled water ([Figure 1c](#F1){ref-type="fig"}). Brains were immersed in the impregnation solution, made by mixing equal volumes of Solution A and B, overnight and then stored in fresh solution for 2 weeks in the dark. Brains were transferred into Solution C overnight and then stored in fresh solution at 4°C for 1 week in the dark. Coronal brain sections (100-μm thickness) were cut on a cryostat (3050S, Leica Microsystems AG, Wetzlar, Germany) with the chamber temperature set at -20°C. Each section was mounted in Solution C on saline-coated microscope slides. After absorption of excess solution, sections were dried naturally at RT. Dried sections were processed following the manufacturer's instructions. Briefly, images of dendrites within DG, CA1, and CA3 of the hippocampus, mPFC and NAc were captured using a 100× objective with a Keyence BZ-9000 Generation microscope (Osaka, Japan). Spines were counted along DG, CA1, CA3, mPFC, and NAc dendrites starting from their point of origin from the primary dendrite, as previously reported ([@CIT0051], [@CIT0045]; [@CIT0051]). For spine density measurements, all clearly evaluable areas containing 50 to 100 μm of secondary dendrites from each imaged neuron were used. To determine relative spine density, spines on multiple dendritic branches from a single neuron were counted to obtain an average spine number per 10 μm. For spine number measurements, only spines that emerged perpendicular to the dendritic shaft were counted. Three neurons per section, 3 sections per animal, and 6 animals were analyzed. The average value for each region in each individual was obtained. These individual averages were then combined to yield a grand average for each region.

Statistical Analysis {#s13}
--------------------

The data show as the mean ± SEM. Analysis was performed using PASW Statistics 20 (formerly SPSS Statistics; SPSS). Comparisons between groups were performed using the 1-way ANOVA followed by posthoc Tukey test. *P* \<.05 was considered statistically significant.

Results {#s14}
=======

MGS0039 Shows Rapid-Acting and Long-Lasting Antidepressant Effects as Ketamine in the Social Defeat Stress Model {#s15}
----------------------------------------------------------------------------------------------------------------

Ketamine produces rapid and long-lasting antidepressant effects in the chronic mild stress model ([@CIT0027]; [@CIT0029]; [@CIT0028]; [@CIT0041]) and social defeat stress model ([@CIT0051], [@CIT0045]; [@CIT0052]). We examined whether MGS0039 showed rapid-acting and long-lasting antidepressant effects in the social defeat stress model. Vehicle, MGS0039 (1.0 mg/kg), or ketamine (10 mg/kg) was injected i.p. into the susceptible mice after social defeat stress ([Figure 1a](#F1){ref-type="fig"}). Locomotion showed no difference (F~3,\ 35~ = 1.240, *P* = .311) among the 4 groups ([Figure 2a](#F2){ref-type="fig"}). In the TST and FST, MGS0039 and ketamine significantly attenuated an increased immobility time in the susceptible mice ([Figure 2b](#F2){ref-type="fig"}-[c](#F2){ref-type="fig"}). One-way ANOVA detected statistical significance in both the TST and FST (TST: F~3,\ 35~ = 4.661, *P* = .008; FST: F~3,\ 35~ = 8.315, *P* \< .001) among the 4 groups ([Figure 2b](#F2){ref-type="fig"}-[c](#F2){ref-type="fig"}). In the SPT, preference of mice after an injection of MGS0039 or ketamine was significantly higher (e: day 15, F~3,\ 35~ = 60.378, *P* \< .001, f: day 19, F~3,\ 35~ = 5.511, *P* = .004) than that of the vehicle-treated group ([Figure 2d](#F2){ref-type="fig"}-[e](#F2){ref-type="fig"}). These behavioral data suggest that MGS0039 promotes rapid and long-lasting antidepressant effects in the social defeat stress model, consistent with ketamine's antidepressant-like effect.

![Antidepressant effects of MGS0039 and ketamine in the social defeat mice. (a) Locomotion test (LMT). (b) Tail suspension test (TST). (c) forced swim test (FST). (d-e) 1% sucrose preference test (SPT). The values represent the mean ± SEM (n = 9). \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001 compared with the vehicle + stress group. Ket, ketamine; MGS, MGS0039; Veh, vehicle.](pyw08902){#F2}

Effects of MGS0039 and Ketamine on Alterations in BDNF-TrkB Signaling and Synaptogenesis in the Selected Brain Regions {#s16}
----------------------------------------------------------------------------------------------------------------------

We performed western-blot analyses of BDNF, TrkB, phosphorylated TrkB (p-TrkB), GluA1, and PSD-95 in selected brain regions (PFC, NAc, DG, CA1, and CA3 of the hippocampus) 8 days after a dose of vehicle (10 mL/kg), MGS0039 (1.0 mg/kg), or ketamine (10 mg/kg) ([Figure 1b](#F1){ref-type="fig"}). Social defeat stress significantly decreased levels of BDNF protein in the PFC, DG, and CA3, but not CA1, while significantly increased BDNF protein in the NAc. MGS0039 significantly attenuated reduced levels of BDNF protein in the PFC and DG of susceptible mice after social defeat stress, although ketamine significantly attenuated reduced levels of BDNF protein in the PFC, DG, and CA3 ([Figure 3a](#F3){ref-type="fig"}). In contrast, 2 compounds did not alter the increased BDNF levels in the NAc ([Figure 3a](#F3){ref-type="fig"}). One-way ANOVA detected statistical significance in BDNF protein (PFC: F~3,\ 23~ = 18.190, *P* \< .001; NAc: F~3,\ 23~ = 9.129, *P* = .001; DG: F~3,\ 23~ = 8.274, *P* = .001; CA1: F~3,\ 23~ = 0.086, *P* = .967; CA3: F~3,\ 23~ = 12.408, *P* \< .001) among the 4 groups ([Figure 3a](#F3){ref-type="fig"}).

![Effects of MGS0039 and ketamine on the brain-derived neurotrophic factor (BDNF) and TrkB phosphorylation in the brain regions. (a) Expression of BDNF in the brain regions. (b) Ratio of phosphorylated TrkB (p-TrkB) to total TrkB in the brain regions. (c) Expression of GluA1 in the brain regions. (d) Expression of postsynaptic density protein 95 (PSD95) in the brain regions. The value was expressed as a percentage of that of control mice. The values represent the mean ± SEM (n = 5 or 6). \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001 compared with the vehicle + stress group. Ket, ketamine; MGS, MGS0039; Veh, vehicle.](pyw08903){#F3}

To clarify the role of TrkB phosphorylation in the action of MGS0039 and ketamine, we performed western-blot analyses of TrkB and p-TrkB, an activated form of TrkB, in samples from PFC, NAc, DG, CA1, and CA3. Social defeat stress significantly decreased the ratio of p-TrkB/TrkB in the PFC, CA3, and DG, but not CA1, while significantly increased the ratio of p-TrkB/TrkB in the NAc. MGS0039 significantly attenuated the reduced ratio of p-TrkB/TrkB in the CA3 of susceptible mice after social defeat stress, although ketamine significantly attenuated the reduced ratio of p-TrkB/TrkB in the PFC, DG, and CA3 ([Figure 3b](#F3){ref-type="fig"}). One-way ANOVA revealed statistical significance in p-TrkB/TrkB (PFC: F~3,\ 23~ = 4.360, *P*=.016; NAc: F~3,\ 23~ = 3.715, *P* = .028; DG: F~3,\ 23~ = 4.168, *P* = .020; CA1: F~3,\ 23~ = 0.337, *P* = .799; CA3: F~3,\ 23~ = 6.889, *P* = .002) among the 4 groups ([Figure 3b](#F3){ref-type="fig"}). In contrast, 2 compounds did not alter the increased ratio of p-TrkB/TrkB in the NAc. These findings suggest that BDNF--TrkB signaling in the PFC, CA3, and DG of hippocampus might be involved in the antidepressant mechanisms of MGS0039 and ketamine.

Proteins such as GluA1, a subtype of the AMPA receptor, and PSD-95 are markers for synaptogenesis ([@CIT0010]; [@CIT0036]). Social defeat stress significantly decreased the levels of GluA1 in PFC, DG, and CA3, but not CA1, while significantly increased GluA1 protein in the NAc. Furthermore, MGS0039 significantly attenuated the reduction of GluA1 in the PFC and DG, although ketamine significantly attenuated the reduction of GluA1 in the PFC, DG, and CA3 ([Figure 3c](#F3){ref-type="fig"}). One-way ANOVA revealed statistical significance in GluA1 protein (PFC: F~3,\ 23~ = 22.322, *P* \< .001; NAc: F~3,\ 23~ = 6.834, *P* = .002; DG: F~3,\ 23~ = 17.683, *P* \< .001; CA1: F~3,\ 23~ = 0.944, *P* = .438; CA3: F~3,\ 23~ = 4.496, *P* = .014) among the 4 groups ([Figure 3c](#F3){ref-type="fig"}). In contrast, MGS0039 and ketamine did not alter the increased levels of GluA1 in NAc ([Figure 3c](#F3){ref-type="fig"}).

Social defeat stress significantly decreased the levels of PSD-95 in the PFC, DG, and CA3, but not CA1, while significantly increased PSD-95 protein in the NAc. Furthermore, MGS0039 significantly attenuated the reduction of PSD-95 in the PFC and DG, although ketamine significantly attenuated the reduction of PSD-95 in the PFC, DG, and CA3 ([Figure 3d](#F3){ref-type="fig"}). One-way ANOVA detected statistical significance in PSD-95 protein (PFC: F~3,\ 23~ = 3.611, *P* = .031; NAc: F~3,\ 23~ = 5.232, *P* = .008; DG: F~3,\ 23~ = 15.554, *P* \< .001; CA1: F~3,\ 23~ = 0.428, *P* = .735; CA3: F~3,\ 23~ = 7.270, *P* = .002) among the 4 groups ([Figure 3d](#F3){ref-type="fig"}). In contrast, MGS0039 and ketamine did not alter the increased levels of PSD-95 in NAc ([Figure 3d](#F3){ref-type="fig"}).

Effects of MGS0039 and Ketamine on Alterations in Dendritic Spine Density in the Selected Brain Regions After Social Defeat Stress {#s17}
----------------------------------------------------------------------------------------------------------------------------------

Social defeat stress causes alterations in dendritic spine density in the medial PFC (mPFC), CA3 and DG of the hippocampus, and NAc (Jiang et al., 2015; [@CIT0052]; [@CIT0051], [@CIT0045]). In this study, we examined whether MGS0039 (1.0 mg/kg) and ketamine (10 mg/kg) could affect alterations in the dendritic spines of the prelimbic (PrL) and infralimbic (IL) regions of mPFC, shell and core of the NAc, and DG, CA1, and CA3 of the hippocampus after social defeat stress. We found significant differences in the PrL of mPFC, NAc core, NAc shell, DG and CA3, but not IL of mPFC and CA1 ([Figure 4](#F4){ref-type="fig"}). Social defeat stress significantly decreased dendritic spine density in the PrL of mPFC, DG, and CA3. Both MGS0039 and ketamine significantly attenuated the reduced spine density seen in the PrL, DG, and CA3 from mice with depression-like phenotype, 8 days after a single dose ([Figure 4a](#F4){ref-type="fig"}, [e](#F4){ref-type="fig"}, [g](#F4){ref-type="fig"}). In contrast, social defeat stress significantly increased dendritic spine density in the NAc core and NAc shell. Neither MGS0039 nor ketamine altered spine density in the NAc of susceptible mice ([Figure 4c](#F4){ref-type="fig"}-[d](#F4){ref-type="fig"}). One-way ANOVA showed statistical significance for all of the examined regions (PrL: F~3,\ 23~ = 64.64, *P* \< .001; IL: F~3,\ 23~ = 0.528, *P* = .668; NAc core: F~3,\ 23~ = 68.45, *P* \< .001; NAc shell: F~3,\ 23~ = 62.44, P \< 0.001; DG: F~3,\ 23~ = 59.75, *P* \< .001; CA1: F~3,\ 23~ = 1.652, *P* = .209; CA3: F~3,\ 23~ = 77.53, *P* \< .001). These findings suggest the role of the PrL of mPFC, DG, and CA3, but not IL of mPFC, NAc, and CA1, in the mechanistic action of MGS0039 and ketamine.

![Effects of MGS0039 and ketamine on alterations in dendritic spine density in the brain regions after social defeat stress. (a) Prelimbic region (PrL) of medial prefrontal cortex (mPFC). (b) Infralimbic region (IL) of mPFC. (c) nucleus Accumbens (NAc) core. (d) NAc shell. (e) Dentate gyrus (DG). (f) CA1. (g) CA3. Scale bar = 10 μm. Values represent the mean ± SEM (n = 6). Representative photomicrographs of Golgi-Cox stained pyramidal neurons in the selected brain regions from animals of each group. \*\*\**P* \< .001 compared with the vehicle + stress group. Ket, ketamine; MGS, MGS0039; Veh, vehicle.](pyw08904){#F4}

Discussion {#s18}
==========

In this study, we found that similar to ketamine, a single dose of MGS0039 promoted rapid and prolonged antidepressant effects in the social defeat stress model. Interestingly, it evoked an antidepressant response 7 days after a single dose in a comparable manner to ketamine ([@CIT0052]). Previous studies showed that, 7 days after a single dose, ketamine could ameliorate anhedonia in rodents under the chronic mild stress model ([@CIT0027]; [@CIT0029]). Therefore, it is noteworthy that these rapid and long-lasting antidepressant effects for MGS0039 in the social defeat stress model bear similarity to the therapeutic effects of ketamine in chronic mild stress or social defeat stress models ([@CIT0027]; [@CIT0029]; [@CIT0051], 2016b; [@CIT0052]). Since ketamine also shows rapid and sustained antidepressant actions in patients with treatment-resistant depression, it is feasible that MGS0039 could promote analogous actions in depressed patients.

Because MGS0039 has been reported to be a selective mGlu2/3 receptor antagonist ([@CIT0007]) and to exhibit both antidepressant and anxiolytic effects ([@CIT0007]; [@CIT0049]) at a dose used in this study, the effect of MGS0039 is mediated through blockade of mGlu2/3 receptor. Moreover, since MGS0039 did not alter general behavioral including locomotion at this dose, it is unlikely that the effect of MGS0039 is attributable to change in general behaviors.

We previously reported conspicuous reductions in the level of BDNF in the PFC, DG, and CA3, but not CA1, of mice susceptible to social defeat stress ([@CIT0051], [@CIT0009]; [@CIT0052]) and learned helplessness rats ([@CIT0039]; [@CIT0051], [@CIT0009]). In this study, we also noted reduced levels of BDNF in the PFC, DG, CA3, but not CA1, of susceptible mice after social defeat stress, but increased BDNF levels in the NAc ([@CIT0039]; [@CIT0039]; [@CIT0039]). Furthermore, we identified that social defeat stress caused decreased phosphorylation of TrkB in the PFC, DG, and CA3 and increased phosphorylation in the NAc. Thus, it is probable that social defeat stress attenuated BDNF--TrkB signaling in PFC and hippocampus (DG and CA3) but increased signals in the NAc, resulting in depression-like behavior in rodents. Compellingly similar to ketamine, MGS0039 significantly lessened the reduction of BDNF in the PFC, DG, and CA3, although it had no effect on the increased BDNF levels seen in the NAc of susceptible mice. Given the role of BDNF--TrkB signaling in the depression-like phenotype ([@CIT0033]; [@CIT0011]; [@CIT0017], [@CIT0018]), just like ketamine, MGS0039 may promote rapid and sustained antidepressant effects by normalizing BDNF levels in the PFC and hippocampus (DG and CA3). This assumption is supported by a previous report that the mGlu2/3 receptor antagonist, LY341495, exerts its antidepressant effect through stimulation of TrkB signaling ([@CIT0023]).

Tracking dendritic morphology, we found opposing changes in spine density between the mPFC, hippocampus, and NAc after social defeat stress. The reduced spine density found in the PrL of mPFC, DG, and CA3 matches the findings seen in rodents under the unpredictable chronic mild stress, inflammation, and learned helplessness models ([@CIT0027]; [@CIT0039]; [@CIT0051], [@CIT0052]; [@CIT0052], [@CIT0045]). In contrast, we found increased spine density in the NAc of depressed mice after social defeat stress, consistent with results from the inflammation and learned helplessness models ([@CIT0051]; [@CIT0052], [@CIT0045]). Moreover, in keeping with ketamine, MGS0039 attenuated the reduced spine density observed in the PrL of mPFC, DG, and CA3, although it had no impact on the increased spine density found in the core and shell of the NAc. Considering the function of synaptogenesis in the action of antidepressants ([@CIT0031]; [@CIT0010]; [@CIT0036]), it is likely that the PrL region of the mPFC, DG, and CA3 of the hippocampus are involved in this drug's action. It should be noted that another mGlu2/3 receptor antagonist, LY341495, elevated synthesis of synaptic proteins in the PFC ([@CIT0013]), strengthening the argument that increased synaptogenesis in the PFC may underpin the antidepressant actions of mGlu2/3 receptor antagonists. In addition, local injection of LY341495 into the mPFC exerts antidepressant effects ([@CIT0015]), indicating the role of the mPFC in the antidepressant action of mGlu2/3 receptor antagonists.

In conclusion, this study shows that like ketamine, MGS0039 can produce rapid and sustained antidepressant effects in the social defeat stress model. Furthermore, it is likely that increased synaptogenesis in the PrL of mPFC and DG and CA3 of the hippocampus after a single dose of MGS0039 may promote this prolonged antidepressant response. Therefore, mGlu2/3 antagonists such as MGS0039 can act as rapid and sustained therapeutic agents for patients with depression, although efficacy and safety of mGlu2/3 receptor antagonists need to be proven in a clinical setting.
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